WAO/EAACI guidelines recommend short-term prophylactic therapy for patients with HAE undergoing these types of procedures, with C1-INH replacement therapies considered the first-line option for short-term prophylaxis (13). The gene discussed is SERPING1; the disease is hereditary angioedema.